Tuberculosis kills more people than any other single infectious disease

Tuberculosis (TB) is the leading cause of death from a single infectious agent worldwide. In 2022, TB caused an estimated 1.3 million deaths globally, according to the World Health Organization. That makes it deadlier than HIV, malaria, or COVID-19 in any single year. The bacterium Mycobacterium tuberculosis spreads through the air when an infected person coughs or sneezes, and it can damage the lungs and other organs if left untreated.

The danger of TB varies sharply depending on whether someone receives treatment. With modern antibiotics, the cure rate for drug-sensitive TB (the most common form) is around 85 percent globally. Without treatment, TB kills roughly half of all people who develop active disease. This gap between treated and untreated TB is the single most important number to understand.

Key Takeaways

  • Tuberculosis caused approximately 1.3 million deaths in 2022, making it the deadliest infectious disease in the world.
  • About 85 percent of people with drug-sensitive TB are cured when they complete a standard course of antibiotics lasting four to six months.
  • Without treatment, TB kills roughly 50 percent of people who develop active disease, often within two years.
  • Drug-resistant TB is harder to treat and has lower cure rates, ranging from 55 to 70 percent depending on the type and the country.
  • Most people infected with TB bacteria never develop active disease because their immune system keeps the infection dormant.

How many people have TB infection versus active disease

The numbers shift dramatically when you separate TB infection from TB disease. An estimated 2.5 billion people worldwide carry TB bacteria in their bodies but do not have active disease. Their immune system has contained the infection, and they cannot spread it to others. These people have latent TB infection.

Only about 5 to 10 percent of people with latent TB infection will ever develop active TB disease. The risk is higher for people with weakened immune systems—such as those with HIV, those taking immunosuppressive medications, or those with severe malnutrition. For most people, latent TB remains dormant for life and never causes illness or death.

Death rates in countries with and without TB treatment access

TB mortality varies enormously by geography and access to treatment. In countries with robust healthcare systems and reliable antibiotic supply, TB death rates are low—typically fewer than 2 deaths per 100,000 people per year. In countries with limited healthcare infrastructure, the rate can exceed 20 deaths per 100,000 people per year.

The difference is almost entirely about treatment access. A person diagnosed with TB in a wealthy country with a functioning health system faces a very different risk than someone in a region where antibiotics are scarce, diagnosis is delayed, or treatment is incomplete. The bacterium itself is equally dangerous; the outcome depends on what happens after diagnosis.

Drug-resistant TB and why it is harder to treat

A smaller but growing portion of TB cases involve bacteria that resist standard antibiotics. Multidrug-resistant TB (MDR-TB) resists at least two of the most powerful first-line drugs. Extensively drug-resistant TB (XDR-TB) resists even more medications. These forms are much harder to cure and require longer, more toxic treatment regimens.

Cure rates for MDR-TB range from 55 to 70 percent depending on the country and the specific drug combination used. XDR-TB cure rates are lower, typically 40 to 60 percent. Drug-resistant TB develops when patients do not complete their full course of antibiotics—the bacteria survive and mutate, becoming resistant to the drugs that would have killed them. This is why completing the entire treatment course, even when symptoms disappear, is critical.

Age and TB death risk

TB can kill at any age, but the risk is not evenly distributed. Children under five with active TB disease have a higher risk of severe complications and death compared to older children, partly because their immune systems are still developing. Elderly people with TB also face higher mortality rates, often because they have other health conditions that complicate treatment.

Adults aged 15 to 49 make up the largest share of TB deaths in absolute numbers, simply because this is the largest population group. However, the death rate per person infected is actually highest in very young children and in people over 65. People with HIV and TB together face the highest mortality risk of all—without antiretroviral therapy, the combination is nearly always fatal.

TB death rates by region

The World Health Organization tracks TB deaths by region. Africa has the highest TB death rate per capita, driven by high HIV prevalence and limited healthcare access. Southeast Asia and the Western Pacific region account for the largest absolute number of TB deaths because of their large populations. Eastern Europe and Central Asia have rising rates of drug-resistant TB, which increases mortality.

These regional differences reflect healthcare capacity, TB screening programs, treatment availability, and the prevalence of HIV—not differences in how dangerous the bacterium is. The same organism causes vastly different outcomes depending on whether it is caught early, whether effective drugs are available, and whether a person can complete treatment without interruption.

What happens to TB mortality with treatment

The transformation in risk once treatment begins is dramatic. A person with active TB disease who starts standard antibiotics typically becomes non-infectious within two weeks. After two months of treatment, the bacteria are usually eliminated from the lungs. After four to six months of completing the full course, the person is cured.

During this treatment period, the risk of death drops sharply. The main causes of death during TB treatment are usually other conditions—untreated HIV, severe malnutrition, or other infections—rather than TB itself. This is why early diagnosis and prompt treatment are the most powerful tools for reducing TB mortality. A person who knows they have TB and takes their medications as prescribed faces a very different outcome than someone who does not know they are infected.

Frequently Asked Questions

Can TB kill you if you take all your antibiotics?

Death during proper TB treatment is rare—roughly 1 to 2 percent of people who complete treatment die, usually from other causes rather than TB itself. If you take all your antibiotics as prescribed and finish the full course, your chance of being cured is around 85 percent for drug-sensitive TB. The main risk is stopping treatment early, which allows the bacteria to survive and become resistant.

Is latent TB dangerous?

Latent TB infection does not make you sick and does not spread to others. However, it can become active TB disease later in life, especially if your immune system weakens. About 5 to 10 percent of people with latent TB will develop active disease at some point. Your doctor may recommend preventive treatment to lower this risk, particularly if you have HIV or other conditions that weaken immunity.

Why is TB more deadly in some countries than others?

TB is deadlier in countries with limited access to antibiotics, delayed diagnosis, and poor treatment completion rates. It is also more common in areas with high HIV prevalence, malnutrition, and overcrowding. The bacterium itself is equally dangerous everywhere; the difference is whether people can get diagnosed and treated before the disease causes severe damage.

What makes drug-resistant TB so dangerous?

Drug-resistant TB requires longer treatment with more toxic medications, and cure rates are lower—55 to 70 percent for MDR-TB instead of 85 percent for standard TB. It develops when patients stop taking antibiotics early, allowing bacteria to survive and mutate. This is why completing your full course of TB treatment, even after you feel better, is critical for everyone's safety.

Can you die from TB even with modern medicine?

Yes, but it is uncommon if you receive treatment. Death from TB during proper treatment usually happens in people with very weak immune systems, severe malnutrition, or other serious illnesses. Without any treatment, TB kills about 50 percent of people who develop active disease. The difference between these two outcomes—treated versus untreated—shows why diagnosis and access to antibiotics are life-or-death matters.